|
| 37945382 | Characterizing Normal Variant [<sup>68</sup>Ga]Ga-FAPI-46 Uptake in the Epididymis. | J Nucl Med | 2024 |
| 35953304 | A 2022 International Survey on the Status of Prostate Cancer Theranostics. | J Nucl Med | 2023 |
| 37562803 | Redesigned Curricula, Stringent Licensing Criteria, and Integrated Independence Are Conditions for a Bright Future for Nuclear Medicine in the United States. | J Nucl Med | 2023 |
| 37857505 | Advancing Nuclear Medicine at the Multiomics Intersection: Johannes Czernin Discusses Innovation and Translation with Kalevi Kairemo. | J Nucl Med | 2023 |
| 37591543 | Toward Integrated Independence: Johannes Czernin Discusses the Future of Theranostics with Ebrahim Delpassand, Eric Rohren, and Wolfgang Weber. | J Nucl Med | 2023 |
| 37797974 | Tandem Isotope Therapy with <sup>225</sup>Ac- and <sup>177</sup>Lu-PSMA-617 in a Murine Model of Prostate Cancer. | J Nucl Med | 2023 |
| 37482512 | Presurgical <sup>68</sup>Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial. | Eur Urol | 2023 |
| 37788851 | Pioneering Research on Cancer Quality of Life and Outcomes: Johannes Czernin Discusses a Half-Century of Whole-Patient Focus with Patricia A. Ganz. | J Nucl Med | 2023 |
| 37788850 | A Tribute to Our <i>JNM</i> Associate Editors. | J Nucl Med | 2023 |
| 37678927 | Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with <sup>177</sup>Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis. | J Nucl Med | 2023 |
| 35738905 | <sup>18</sup>F-FDG PET Visualizes Systemic STING Agonist-Induced Lymphocyte Activation in Preclinical Models. | J Nucl Med | 2023 |
| 37321828 | PSMA-Negative Lesion Progression Under <sup>177</sup>Lu-PSMA Radioligand Therapy. | J Nucl Med | 2023 |
| 37321822 | [<sup>68</sup>Ga]Ga-FAPI-46 PET for Visualization of Postinfarction Renal Fibrosis. | J Nucl Med | 2023 |
| 37055221 | Looking at the Future of Prostate Cancer Treatment: A Conversation Between Michael Morris, Jeremie Calais, and Johannes Czernin. | J Nucl Med | 2023 |
| 37399312 | <i>JNM</i> Editors' Choice Awards for 2022. | J Nucl Med | 2023 |
| 37399311 | Leading the European Society of Cardiology: A Conversation Between Franz Weidinger, Frank Bengel, and Johannes Czernin. | J Nucl Med | 2023 |
| 37333052 | Fibroblast Activation Protein Expression in Sarcomas. | Sarcoma | 2023 |
| 37230532 | Obstructive Sialadenitis from Oral Squamous Cell Carcinoma: [<sup>68</sup>Ga]Ga-FAPI-46 PET-Positive and [<sup>18</sup>F]FDG PET-Negative. | J Nucl Med | 2023 |
| 36997329 | PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [<sup>177</sup>Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective Study. | J Nucl Med | 2023 |
| 36725247 | Advancing Clinical Trial Innovation in Pancreatic Cancer: A Conversation Between Diane Simeone, Ken Herrmann, and Johannes Czernin. | J Nucl Med | 2023 |
| 36581376 | Incidental Focal <sup>68</sup>Ga-FAPI-46 Uptake in a Urachal Remnant: A Potential Pitfall Mimicking a Malignant Peritoneal Lesion. | J Nucl Med | 2023 |
| 36635088 | Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate Cancer. | J Nucl Med | 2023 |
| 36797449 | LUNAR: a randomized Phase 2 study of <sup>177</sup> Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol). | BJU Int | 2023 |
| 36599476 | From Physician to Leader in Global Research and Development: A Conversation Between Ken Song, Lisa Bodei, and Johannes Czernin. | J Nucl Med | 2023 |
| 36599472 | Thank You Drs. Ziessman and Knight for Your Many Years of Newsline Coverage. | J Nucl Med | 2023 |
| 36863780 | The <sup>177</sup>Lu-PSMA-617 (Pluvicto) Supply Problem Will Be Solved by Competition. | J Nucl Med | 2023 |
| 36863416 | Patterns of Failure in Men With Radiorecurrent Prostate Cancer: A Post Hoc Analysis of 3 Prospective Gallium 68 Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Imaging Trials. | Int J Radiat Oncol Biol Phys | 2023 |
| 35986643 | Targeting deoxycytidine kinase improves symptoms in mouse models of multiple sclerosis. | Immunology | 2023 |
| 32958451 | Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center Study. | Eur Urol Oncol | 2022 |
| 35772954 | More Unacceptable Denials: Now It's PSMA-Targeted PET/CT Imaging. | J Nucl Med | 2022 |
| 35649664 | How Many Theranostics Centers Will We Need in the United States? | J Nucl Med | 2022 |
| 35422442 | Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter Study. | J Nucl Med | 2022 |
| 36215517 | A Life in Nuclear Medicine in Israel: A Conversation Between Ora Israel and Johannes Czernin. | J Nucl Med | 2022 |
| 36182983 | Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225. | EJNMMI Res | 2022 |
| 35914829 | Practicing Medicine in Wartime Ukraine: A Conversation Between Yaroslav Kmetyuk, Johannes Czernin, and Ken Herrmann. | J Nucl Med | 2022 |
| 33602654 | Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging. | Eur Urol Oncol | 2022 |
| 35101926 | A European Oncology Leader Looks at PSMA: A Conversation Between Silke Gillessen, Johannes Czernin, and Ken Herrmann. | J Nucl Med | 2022 |
| 34980666 | Advancing Nuclear Medicine in Australia over 3 Decades: A Conversation Between Rodney Hicks, Johannes Czernin, and Ken Herrmann. | J Nucl Med | 2022 |
| 35273096 | Outcome of Patients with PSMA PET/CT Screen Failure by VISION Criteria and Treated with <sup>177</sup>Lu-PSMA Therapy: A Multicenter Retrospective Analysis. | J Nucl Med | 2022 |
| 35232878 | Health Care and Nuclear Medicine in France: A Conversation Between Dominique Le Guludec, Johannes Czernin, and Jérémie Calais. | J Nucl Med | 2022 |
| 34740953 | Correlation of [68]Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study. | J Nucl Med | 2022 |
| 34620731 | PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: An International Multicenter Study. | J Nucl Med | 2022 |
| 34593596 | <sup>18</sup>F-FLT PET/CT as a Prognostic Imaging Biomarker of Disease-Specific Survival in Patients with Primary Soft-Tissue Sarcoma. | J Nucl Med | 2022 |
| 34649942 | Head-to-Head Comparison of <sup>68</sup>Ga-PSMA-11 PET/CT and mpMRI with a Histopathology Gold Standard in the Detection, Intraprostatic Localization, and Determination of Local Extension of Primary Prostate Cancer: Results from a Prospective Single-Center Imaging Trial. | J Nucl Med | 2022 |
| 34326126 | A Comprehensive Assessment of <sup>68</sup>Ga-PSMA-11 PET in Biochemically Recurrent Prostate Cancer: Results from a Prospective Multicenter Study on 2,005 Patients. | J Nucl Med | 2022 |
| 34272317 | 18F-FDG PET/CT Imaging Biomarkers for Early and Late Evaluation of Response to First-Line Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma. | J Nucl Med | 2022 |
| 34215673 | A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for <sup>68</sup>Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors. | J Nucl Med | 2022 |
| 34049987 | Tumor Sink Effect in <sup>68</sup>Ga-PSMA-11 PET: Myth or Reality? | J Nucl Med | 2022 |
| 32646877 | Immune-Checkpoint Blockade Enhances <sup>225</sup>Ac-PSMA617 Efficacy in a Mouse Model of Prostate Cancer. | J Nucl Med | 2021 |
| 33547207 | Reply: Radioguided Surgery. | J Nucl Med | 2021 |